Writing on product systems, fintech infrastructure, market behavior, and leadership lessons from practical execution.
📚 Books
Beyond platform leadership and infrastructure design, I write about trading psychology, financial literacy, and structured market participation.
Both books are published globally on Amazon (Kindle & Paperback editions available).
🟦 The Mind Game of Trading
Mastering Psychology for Consistent Profits
By Sreenivasulu Malkari
Overview
Trading success is rarely limited by strategy. It is limited by psychology.
In The Mind Game of Trading, I distill 15+ years of real-world trading experience into a structured framework for mastering discipline, emotional control, and execution integrity.
The book focuses on:
• Identifying hidden cognitive biases
• Structured journaling & checklist systems
• Emotional risk management
• Practical trading plan templates
• Long-term consistency frameworks
This is not a theory book — it is a practical discipline manual for traders at all levels.
🔗 Available on Amazon (Paperback & Kindle)
👉 https://www.amazon.com/dp/B0FNKGB7W2
🟦 The Stock Market Starter Kit
Learn to Trade Smart in 7 Days
By Sreenivasulu Malkari
Overview
Designed for beginners entering the Indian stock market, this book simplifies complex concepts into a structured 7-day learning framework.
It emphasizes structured thinking, capital protection, and long-term consistency as the core pillars of intelligent market participation.
It covers:
• How stock markets function (NSE/BSE context)
• Intraday, swing & long-term trading basics
• Risk management principles
• Chart reading fundamentals
• Practical checklists and action plans
Clear. Structured. Actionable.
🔗 Available on Amazon (Paperback & Kindle)
👉 https://www.amazon.com/dp/B0FF2NK8MV
-
Harsha Engineers Shares Upgraded To ‘Buy’ By IDBI Capital: A Comprehensive Analysis
Harsha Engineers Shares Upgraded To ‘Buy’ By IDBI Capital: A Positive Outlook Harsha Engineers International Ltd. has delivered a strong set of Q2 results, prompting IDBI Capital to upgrade the stock to ‘Buy’ with a potential upside of 20%. The company’s revenue grew by 7% year-over-year (YoY), while Ebitda surged by 28% YoY to Rs…
-
India and China: A Tale of Two Markets with Different Fundamentals
Introduction to the Indian and Chinese Markets The Indian and Chinese stock markets have been making headlines in recent times, with China experiencing a resurgence in its stock market, while India has been underperforming. According to Mark Matthews, Head of Research Asia at Julius Baer, these two markets are driven by different fundamentals and opportunities,…
-
Indigo Paints Q2 Review: A Closer Look at the Company’s Performance and Future Prospects
Indigo Paints Q2 Review: A Detailed Analysis Indigo Paints Ltd. has reported a strong Q2 performance, with revenue growth of 4.2% YoY, outperforming its key peers Kansai Nerolac, Berger Paints, and Akzo Nobel. The company’s Ebitda margin expansion of +106bps is also a notable achievement, especially when compared to the margin contractions seen by Berger…
-
Lenskart IPO: Ambit Gives Sell Rating, Cites Valuation Concerns
Lenskart IPO: Ambit Gives Sell Rating, Cites Valuation Concerns Lenskart, the popular eyewear retailer, is set to list on the Indian stock markets on Monday, but has already received its first sell rating from Ambit, a leading brokerage firm. The rating comes as a surprise, given Lenskart’s strong brand and growth prospects. However, Ambit believes…
-
Hindalco Q2 Results: Strong Performance by India Business Drives 21% Profit Rise
Hindalco Q2 Results: Strong Performance by India Business Drives 21% Profit Rise Aditya Birla Group’s metals arm Hindalco Industries Ltd has reported a 21.2% rise in consolidated profit after tax at Rs 4,741 crore in the quarter ended September 2025. This significant increase can be attributed to the strong performance by the India business, disciplined…
-
Indoco Remedies Q2 Review: Dolat Capital Revises Target Price, Maintains ‘Sell’ Rating
Indoco Remedies Q2 Review: A Mixed Bag for Investors Indoco Remedies Ltd., a leading Indian pharmaceutical company, recently announced its Q2 FY26 earnings, which came in above estimates. However, despite the positive earnings surprise, Dolat Capital has downgraded its Ebitda estimates and maintained a ‘Sell’ rating with a revised target price of Rs 224. Q2…